Core Insights - Intuitive Surgical, Inc. reported preliminary fourth-quarter and full-year 2025 results, showing growth in procedures, system placements, and revenue despite a stock decline of 4.24% on the announcement day [1][6] Procedure Expansion - Worldwide procedures using da Vinci and Ion systems increased by approximately 18% in Q4 2025 compared to the previous year, with da Vinci procedures rising by about 17% and Ion procedures surging by around 44% [2] - For the full year 2025, combined procedures grew approximately 19% compared to 2024, with expectations of a 13% to 15% growth in global da Vinci procedures in 2026 [2] System Placements - In Q4 2025, the company placed 532 da Vinci surgical systems, including 303 da Vinci 5 units [3] - For the entire year, Intuitive placed 1,721 da Vinci systems, although there were fewer Ion endoluminal system placements earlier in the year compared to 2024 [3] Revenue Performance - Preliminary revenue for Q4 2025 was about $2.87 billion, exceeding the Street's expectation of $2.72 billion, marking a 19% increase from Q4 2024 [4] - Total revenue for the full year reached approximately $10.06 billion, reflecting a 21% increase from 2024, driven by higher procedure volumes and increased system placements [4] - Revenue from instruments and accessories grew around 17% in Q4, while full-year revenue for these segments rose about 19% compared to the prior year [5] Management Commentary - CEO Dave Rosa highlighted wider platform adoption and growing procedure volumes, emphasizing the company's commitment to improving patient care and outcomes [5]

Company Overview - ClearPoint Neuro Inc. operates in two segments: providing medical devices for neurosurgical applications and focusing on partnerships in the biologics and drug delivery space [2] - The primary product is the ClearPoint system, which targets the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain [2] Recent Developments - The ClearPoint Prism Neuro Laser Therapy System received FDA clearance to include 1.5T MRI guidance, expanding its market opportunity in the U.S., where 1.5T MRI systems account for approximately 60% of clinical use [3] - The company began commercialization of the ClearPoint Prism Neuro Laser Therapy System in 2022 [2] Financial Performance - For the full year 2024, revenue was reported at $31.4 million, reflecting a 31% increase over 2023 [4] - The company expects revenue for 2025 to range between $36.0 million and $41.0 million, which would mark the 11th consecutive year of annual revenue growth if achieved [4][5] Stock Performance - ClearPoint Neuro's stock has seen significant movement, trading around $5.50 in May 2024 and reaching a high of $19.22 on February 6, 2025, before pulling back [5] - As of the latest trading, the stock is up nearly 40% at $17.01 in premarket trading [1][5]